ArticleBMC biology2025
Interpretable multi-instance heterogeneous graph network learning modelling CircRNA-drug sensitivity association prediction.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- AGCECDA: attention-guided heterogeneous graph collaborative embedding for circRNA-drug sensitivity association prediction.BMC biology · 2026Article
- CFGSCDSA: Predicting circRNA-drug sensitivity associations based on collaborative feature learning and graph structure learning.PLoS computational biology · 2026Article
- Circular RNA therapeutics: a new class of long-acting RNA medicines for oncology, immunology, and rare diseases.Frontiers in immunology · 2026Review
- Hypergraph Learning with Hyperedge Gating and Multiscale Topology Feature Learning for Predicting Disease-Related circRNAs.ACS omega · 2025Article
- CircZFR functions in cancer from molecular networks to precision therapy.Frontiers in genetics · 2025Review
- DMAGCL: A dual-masked adaptive graph contrastive learning framework for predicting circRNA-drug sensitivity.Frontiers in genetics · 2025Article
- Computational discovery of natural medicines targeting adenosine receptors for metabolic diseases.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDifferent expression levels of circular RNAs (circRNAs) affect the sensitivity of human cells to drugs, thus producing different responses to the therapeutic effects of drugs. Using traditional biomedical experiments to discover and confirm sensitivity relationships is not only time-consuming but also costly. Therefore, developing an effective method to accurately predict new associations between circRNAs and drug sensitivity is crucial and urgent. Therefore, we constructed a heterogeneous graph network MiGNN2CDS on the basis of multi-instance learning (MIL).
resultsWe first extracted similar features of circRNAs and drugs and the structural features of drugs to construct a heterogeneous network. To learn the deep embedding features of the heterogeneous network, we designed a heterogeneous graph convolutional network (GCN) architecture. By introducing instance learning, we subsequently designed a pseudo-metapath instance generator and a bidirectional translation embedding projector BiTrans to learn the metapath-level representation of circRNA-drug pairs. Finally, an interpretable multiscale attention network joint predictor was designed to achieve accurate prediction and interpretable analysis of circRNA-drug sensitivity associations.
conclusionsMiGNN2CDS achieves better prediction accuracy than many state-of-the-art models do. Case studies show that MiGNN2CDS can effectively predict unknown associations, and the model interpretability of MiGNN2CDS is verified by high-confidence meta-path analysis. The code and data are available at https://github.com/nmt315320/MiGNN2CDS.git .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.